Brian Park, PharmD

Drug Information Specialist https://www.renalandurologynews.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

News

FDA to Review Wearable Furosemide Delivery System for Outpatient Use

Brian Park, PharmD

May 18, 2022

Furoscix is a wearable, pre-programmed on-body furosemide delivery system for outpatient self-administration.

Hemodialysis

FDA Warns of Potential Chemical Exposure With Certain Hemodialysis Machines

Brian Park, PharmD

May 11, 2022

The source of the chemicals is from the silicone tubing used as a part of the hydraulics in the machine and the dialysate lines.

Kidney Cancer

Trials Investigating Bempegaldesleukin in Combination With Nivolumab Discontinued

Brian Park, PharmD

April 29, 2022

The decision to discontinue was based on data from pre-planned analyses of the phase 3 PIVOT-09 study and the phase 2 PIVOT-10 study.

Prostate Cancer

Camcevi Now Available for Advanced Prostate Cancer Treatment

Brian Park, PharmD

April 7, 2022

Camcevi is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, a gonadotropin-releasing hormone agonist.

Bladder Cancer

Sacituzumab Govitecan Plus Pembrolizumab Promising for Metastatic Urothelial Cancer After Failure With Platinum-Based Regimen

Brian Park, PharmD

April 6, 2022

Cohort 3 of the phase 2 TROPHY-U-01 trial evaluated sacituzumab govitecan plus pembrolizumab in checkpoint inhibitor-naive adults with metastatic urothelial cancer who progressed after platinum-based chemotherapy.

Hypogonadism

FDA Approves Oral Testosterone Replacement Therapy Tlando

Brian Park, PharmD

April 6, 2022

The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Tlando in 95 adult hypogonadal male patients.

Prostate Cancer

Talabostat Plus Pembrolizumab Promising for mCRPC With Adenocarcinoma Phenotype

Brian Park, PharmD

April 5, 2022

At a median follow-up of 12 weeks, results showed that the composite response rate was 23%.

Anemia

FDA Says No to Vadadustat Approval Due to Safety Concerns

Brian Park, PharmD

April 4, 2022

The NDA submission included data from 36 clinical trials involving over 8000 patients.

Bladder Cancer

Pembrolizumab Plus Lenvatinib Not Superior to Pembrolizumab Alone in Advanced Urothelial Carcinoma

Brian Park, PharmD

April 1, 2022

The phase 3 LEAP-011 study evaluated pembrolizumab plus lenvatinib vs placebo in 441 adults with histologically confirmed, locally advanced or metastatic urothelial carcinoma.